Oxford BioMedica is a gene and cell therapy company. The company is engaged in lentiviral vector and cell therapy research, development and production. The company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners. The R&D segment is engaged in the development of in-vivo and ex-vivo gene and cell therapy products, and the development of lentivirus-related platform technology. OXB provides a platform of technologies and capabilities with which it designs, develops and produces gene and cell-based medicines. The company’s product pipeline of OXB-102, OXB-201, OXB-202 and OXB-302 addresses neurodegenerative and ocular diseases, and a range of cancers. OXB-102 is indicated for Parkinson’s disease. OXB-202 is indicated for Ocular (corneal graft rejection). OXB-302 is indicated for cancer disease. Its OXB-201 is indicated for wet age-related macular degeneration.
A post was merged into an existing topic: Oxford BioMedica plc - OXB